Kairos Pharma (NYSE American: KAPA) Advancing New Strategies to Overcome Cancer Treatment Challenges

The global oncology landscape is on the brink of transformation, with cancer cases expected to rise sharply, particularly in lower-income countries. This growing demand for cancer treatments has driven global spending on oncology medicines to $223 billion in 2023, with a projected increase to $409 billion by 2028. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, is steadily building a presence in the oncology space, focusing on therapies aimed at overcoming cancer drug resistance and immune suppression. Kairos has developed a promising pipeline that could attract attention, with its most notable candidate being ENV105, a therapy designed to target the mechanisms that allow tumors to evade treatment. ENV105 works by inhibiting the CD105 protein, enhancing the effectiveness of existing cancer treatments, and its associated biomarker can predict patient responses before treatment begins. The results from recent clinical trials of ENV105 are promising, and Kairos Pharma has partnered with PreCheck Health Services to develop companion biomarkers that will identify which patients are most likely to benefit from the therapy. The company recently debuted on the NYSE American under the ticker symbol “KAPA,” successfully raising $6.2 million through its initial public offering.